An Open-label, Phase I Multicenter, Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Checkpoint Inhibitor Monotherapy in Patients With Solid Tumors
Latest Information Update: 03 Jul 2025
At a glance
- Drugs Oral T-cell immunotherapies-NEC Corporation/VAXIMM (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
Most Recent Events
- 26 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 16 May 2024 Planned number of patients changed from 6 to 15.
- 16 May 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.